Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Stanford University
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01108497
First received: April 20, 2010
Last updated: October 28, 2013
Last verified: October 2013
  Purpose

We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of diagnosis and (b) more accurately choose the best therapy for each patient.


Condition Intervention
Leukemia
Procedure: Bone Marrow Aspiration

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Gene Expression [ Time Frame: days 0, 8, 22 or 29 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

bone marrow


Estimated Enrollment: 120
Study Start Date: July 2001
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible.

Criteria

Inclusion Criteria:1. All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible. There is no bias in regards to age range, gender or ethnic background.

2. Signed informed consent

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01108497

Contacts
Contact: Norman J Lacayo (650) 723-5535 lacayon@stanford.edu

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Norman J Lacayo    650-723-5535    lacayon@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Norman James Lacayo         
Sub-Investigator: Atul J Butte         
Sub-Investigator: James M Ford         
Sub-Investigator: Hanlee P. Ji         
Sub-Investigator: Yasodha Natkunam         
Sub-Investigator: Garry Philip Nolan         
Sub-Investigator: Maureen M. O'Brien         
Sub-Investigator: Joshua D Schiffman         
Sub-Investigator: Branimir I Sikic         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Norman James Lacayo Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01108497     History of Changes
Other Study ID Numbers: PEDSHEM0001, 11062, SU-09112009-3881
Study First Received: April 20, 2010
Last Updated: October 28, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on September 16, 2014